Hexagon Nutrition IPO is a book-built public issue aggregating to ₹138.87 crore and is entirely an offer for sale of 3.09 crore equity shares. The IPO will open for subscription on June 5, 2026, and close on June 9, 2026. The company has fixed the price band at ₹42 to ₹45 per share.
Retail investors can apply for a minimum lot size of 333 shares, requiring an investment of ₹14,985 at the upper end of the price band. For sNII investors, the minimum application size is 14 lots or 4,662 shares, amounting to ₹2.09 lakh, while bNII investors need to apply for 67 lots or 22,311 shares worth around ₹10.04 lakh.
The basis of allotment is expected to be finalised on June 10, 2026, and the shares are likely to list on NSE and BSE on June 12, 2026. Cumulative Capital Pvt. Ltd. is acting as the book-running lead manager, while Kfin Technologies Ltd. has been appointed as the registrar for the IPO.
Company Overview
Founded in 1993, Hexagon Nutrition Ltd. is a research-focused nutrition company engaged in developing and manufacturing a wide range of health and nutrition products. Its portfolio includes micronutrient premixes, wellness and clinical nutrition products, therapeutic foods, and ready-to-use nutritional solutions.
The company owns popular brands such as Pentasure, Obesigo, Pediagold, and Nutrone, catering to different age groups and health requirements. Hexagon Nutrition also supplies customised vitamin and mineral premixes to major FMCG companies and works with international organisations on food fortification and nutrition initiatives. Its products are exported to more than 75 countries.
The company operates manufacturing facilities in Nasik, Chennai, and Thoothukudi in India, along with an overseas unit in Tashkent, Uzbekistan. The Chennai and Thoothukudi plants are located in SEZ zones, offering logistical and operational advantages for exports and imports.
(Source: RHP)
Industry Context
- The global nutrition industry is witnessing strong demand for personalised, preventive, and functional nutrition products, driven by ageing populations, rising healthcare awareness, and increasing consumer preference for clean-label and wellness-focused food solutions across developed and emerging markets.
- India’s nutrition sector is expanding rapidly due to growing health awareness, higher demand for fortified foods, and increasing acceptance of preventive healthcare solutions, creating long-term growth opportunities for companies operating in clinical and wellness nutrition categories.
- Malnutrition continues to remain a major healthcare challenge in India, especially among women and children, highlighting the need for affordable nutritional products, therapeutic foods, and micronutrient solutions to improve public health and dietary outcomes.
- Rising focus on food fortification, dietary supplements, and clinical nutrition by governments, healthcare organisations, and consumers is expected to support sustained growth in the nutrition industry, benefiting companies with diversified product portfolios and strong manufacturing capabilities.
(Source: RHP)
Business Strengths
- Hexagon Nutrition operates an integrated nutrition business covering research, product development, manufacturing, marketing, and distribution, enabling consistent quality control and scalable operations across nutrition categories globally.
- The company is among India’s leading premix manufacturers, supplying customised vitamin and mineral formulations to major domestic and multinational FMCG companies across multiple food categories.
- Hexagon Nutrition has built recognised wellness brands including Pentasure, Obesigo, Pediagold, and Nutrone, supported by regulatory approvals across several international markets and growing healthcare professional outreach.
- The company benefits from long-standing customer relationships across consumer, FMCG, and public health segments, with repeat business contributing significantly to operational stability and revenue visibility.
- Hexagon Nutrition has strong manufacturing and research capabilities, supported by multiple production facilities, dedicated R&D centres, international certifications, and an extensive omnichannel distribution network across India and overseas markets.
(Source: RHP)
Financial Performance
Hexagon Nutrition Limited – Financials (₹ in Million)
| Particulars | 31 Dec 2025 | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|---|
| Revenue from operations | 2,675.87 | 3,249.29 | 2,977.31 | 2,785.01 |
| Total Income | 2,755.70 | 3,312.87 | 3,046.21 | 2,816.46 |
| Profit After Tax | 270.33 | 243.77 | 122.14 | 58.24 |
| EBITDA | 375.54 | 400.72 | 248.77 | 171.74 |
| Return on Equity (RoE) | 13.02% | 10.47% | 7.21% | 3.50% |
| Return on Capital Employed (ROCE) | 14.82% | 17.06% | 11.12% | 5.94% |
| Debt To Equity Ratio | 0.18 | 0.14 | 0.21 | 0.32 |
(Source: RHP)
Key Ratios & Metrics (Annualised)
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 13.02% | 10.47% |
| ROCE | 14.82% | 17.06% |
| Debt/Equity | 0.18 | 0.14 |
| RoNW | 12.12% | 12.46% |
| PAT Margin | 9.81% | 7.36% |
| EBITDA Margin | 14.03% | 12.33% |
| Price to Book Value | 2.48 | 2.83 |
(Source: RHP)
IPO Details
| Particulars | Details |
|---|---|
| IPO Date | 5 – 9 June, 2026 |
| Allotment | Wed, June 10, 2026 |
| Listing Date | Fri, June 12, 2026 |
| Face Value | ₹1 per share |
| Price Band | ₹42 to ₹45 per share |
| Lot Size | 333 Shares |
| Issue Type | Book Building IPO |
| Sale Type | Offer for Sale (OFS) |
| Total Issue Size | 3,08,59,704 shares (agg. up to ₹139 Cr) |
| Minimum Retail Investment | ₹14,985 (1 lot/333 shares) |
| Maximum Retail Investment | ₹1,94,805 (13 lots/ 4,329 shares) |
| Listing Exchange | BSE, NSE |
(Compiled from RHP and market updates)
Conclusion
Hexagon Nutrition IPO offers investors exposure to India’s growing nutrition and wellness industry, supported by rising demand for preventive healthcare, fortified foods, and clinical nutrition products. The company has built a diversified portfolio across consumer wellness, premix formulations, and therapeutic nutrition, backed by established manufacturing and research capabilities.
While the business benefits from strong industry tailwinds and global presence, investors should carefully evaluate the company’s financials, competitive positioning, valuation, and overall market conditions before making any investment decision.
Disclaimer: Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. This content is purely for informational purposes only and should not be considered as investment advice or a recommendation. Securities quoted are for illustration purposes only and not recommendatory. Investors are requested to do their own due diligence before investing.
Paytm Money Ltd. SEBI Reg. No. Broking – INZ000240532; Depository Participant – IN – DP – 416 – 2019, Depository Participant Number: CDSL – 12088800. Trading and clearing member of NSE (90165, M52073), BSE (6707), MCX (57525), NCDEX (1315, M51110), and MSEI (85300). SEBI Reg. No. Research Analyst – INH000020086. Regd. Office: 136, 1st Floor, Devika Tower, Nehru Place, Delhi – 110019. For complete Terms & Conditions and Disclaimers visit: https://www.paytmmoney.com/stocks/policies/terms
